MétaCan
Menu
Back to cohort
Record W2564763846 · doi:10.1016/s1525-0016(16)33684-x

79. Development and Validation of a Globally Portable Platform for Lentivirus Mediated Hematopoietic Stem Cell Gene Therapy

2015· article· en· W2564763846 on OpenAlexaff
Jennifer E. Adair, Kevin G. Haworth, Guy Sauvageau, Shelly Heimfeld, Hans‐Peter Kiem

Bibliographic record

VenueMolecular Therapy · 2015
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicVirus-based gene therapy research
Canadian institutionsUniversité de MontréalInstitute for Research in Immunology and Cancer
Fundersnot available
KeywordsHaematopoiesisCD34Progenitor cellBone marrowGenetic enhancementStem cellTransduction (biophysics)Hematopoietic stem cellCell therapyImmunologyMedicineBiologyCell biologyGeneBiochemistry

Abstract

fetched live from OpenAlex

Lentivirus (LV) mediated gene therapy of CD34+ hematopoietic stem and progenitor cells (HSPCs) has demonstrated clinical success for a variety of diseases. However, current state-of-the-art requires ex vivo HSPC gene transfer in a dedicated Good Manufacturing Practices (GMP) facility, limiting treatment to highly developed countries capable of supporting GMP infrastructure. We developed a flexible, overnight platform for efficient isolation and LV gene modification of bone marrow and mobilized peripheral blood CD34+ HSPCs in a closed, table top system, the Prodigy CliniMACS™, with limited requirement for additional equipment. We performed all experiments with only a biosafety cabinet and personal protective equipment to simulate anticipated conditions in clinical facilities of underdeveloped countries. Given the economic burden of mobilization, we initially designed the process for bone marrow. A total of 7 custom programs were developed based on current device memory limitations: (1) hetastarch sedimentation to deplete red blood cells (RBCs), (2) labeling CD34+ cells in the RBC-depleted product, (3) immunomagnetic enrichment of CD34+ cells, (4) initial transduction (MOI = 20 IU/cell), (5) culture overnight, (6) second transduction (MOI = 20 IU/cell) and additional culture, and (7) harvest and formulation of the final product. Addition of a pyrimidoindole derivative, UM729, permitted efficient transduction of CD34+ HSPCs in £18 hours. The process took <36 hours from bone marrow collection to infusion of the gene modified cell product, with £3 hours hands-on time. Autologous, LV gene-modified CD34+ HSPCs from two nonhuman primates produced using this platform engrafted and supported multilineage hematopoietic repopulation after myeloablative total body irradiation. Total cell doses achieved were 27 × 107 and 5.4 × 107 CD34+ cells/kg body weight, respectively. Transduction efficiency in colony-forming units was 23% and 39%, respectively. We observed stable, persistent gene marking in peripheral blood cells up to 16% within one month after infusion. Neither animal displayed evidence for increased toxicity, including potential contamination from the cell product. We then validated processing of human mobilized apheresis products. We demonstrate efficient isolation of human CD34+ HSPCs and up to 60% transduction efficiency with a clinical-grade LV currently being tested in a phase I clinical trial for treatment of HIV-associated lymphoma. Immediate release criteria for product infusion were met (negative gram stain, endotoxin <5 EU/mL and cell viability >70%). Perform-and-report testing and xenotransplantation of these gene-modified cells into immunodeficient mice for further functional testing are in progress. These data demonstrate preclinical safety and feasibility of this portable strategy for ex vivo LV gene transfer into HSPCs, representing the first globally applicable advance in translation of HSPC gene therapy.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.017
Threshold uncertainty score0.928

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.041
GPT teacher head0.287
Teacher spread0.246 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueMolecular TherapySame topicVirus-based gene therapy researchFrench-language works237,207